Current role
Dr. Nicholas Botwood
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Dr. Nicholas Botwood
Syndax Pharmaceuticals Inc reported in an 8-K filed May 16, 2025 that Dr. Nicholas Botwood was appointed Head of Research and Development (R&D) and Chief Medical Officer.
“Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-05-16–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Syndax Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Michael A. Metzger CEO, Board Member
- Michael Metzger CEO
- Daphne Karydas CFO
- Keith A. Goldan CFO
- Keith Goldan CFO
- Luke J. Albrecht General Counsel
- Aleksandra Rizo, M.D., Ph.D. Board Member
- Martin H. Huber, M.D. Board Member
- Pierre Legault Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.